Aller au contenu principal

 Articles scientifiques

Pre-existing evidence and outcome of phase III trials in gastrointestinal oncology: a systematic review.

Auteurs : Bregni G, Trevisi E, Saude Conde R, Vanhooren M, Akin Telli T, Assaf I, Hendlisz A, Di Maio M, Sclafani F
Année : 2023
Journal : J Natl Cancer Inst

Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.

Auteurs : Akin Telli T, Bregni G, Vanhooren M, Saude Conde R, Hendlisz A, Sclafani F
Année : 2022
Journal : Cancer Treat Rev
Volume : 110
Pages : 102460

Circulating DNA in the neoadjuvant setting of early stage colon cancer.

Auteurs : Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, DHondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, Sclafani F
Année : 2022
Journal : Acta Oncol
Volume : 61
Pages : 1223-1229

JCOG0603: Are We Really Sure This Was a Negative Trial?

Auteurs : Saude Conde R, Bregni G, Saad E, Hendlisz A, Sclafani F
Année : 2022
Journal : J Clin Oncol
Volume : 40
Pages : 803-805

Toward Targeted Therapies in Oesophageal Cancers: An Overview.

Auteurs : Bregni G, Beck B
Année : 2022
Journal : Cancers (Basel)
Volume : 14

Regorafenib Induces Senescence and Epithelial-Mesenchymal Transition in Colorectal Cancer to Promote Drug Resistance.

Auteurs : Kehagias P, Kindt N, Krayem M, Najem A, Agostini G, Acedo Reina E, Bregni G, Sclafani F, Journe F, Awada A, Ghanem GE, Hendlisz A
Année : 2022
Journal : Cells
Volume : 11

Mind the target: human epidermal growth factor receptor 2 in colorectal cancer.

Auteurs : Saude Conde R, Rasschaert G, Bregni G, Hendlisz A, Sclafani F
Année : 2022
Journal : Curr Opin Oncol
Volume : 34
Pages : 382-388

Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.

Auteurs : Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, DHondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F
Année : 2021
Journal : Acta oncol (Stockholm)
Volume : 60
Pages : 549-553

Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials.

Auteurs : Giunta EF, Bregni G, Hendlisz A, Sclafani F
Année : 2021
Journal : Curr Opin Oncol
Volume : 33
Pages : 372-377

Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.

Auteurs : Giunta EF, Bregni G, Pretta A, Deleporte A, Liberale G, Bali MA, Moretti L, Troiani T, Ciardiello F, Hendlisz A, Sclafani F
Année : 2021
Journal : Cancer Treat Rev
Volume : 96
Pages : 102177

Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives.

Auteurs : Personeni N, Smiroldo V, Giunta EF, Prete MG, Rimassa L, Bregni G, Sclafani F
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.

Auteurs : Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, DHondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F
Année : 2021
Journal : Clin Colorectal Cancer
Volume : 20
Pages : 326-333

Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18 F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial.

Auteurs : Camera S, Akin Telli T, Woff E, Vandeputte C, Kehagias P, Guiot T, Critchi G, Wissam Y, Bregni G, Trevisi E, Pretta A, Senti C, Leduc S, Gkolfakis P, Hoerner F, Rothé F, Sclafani F, Flamen P, Deleporte A, Hendlisz A
Année : 2020
Journal : Cancers (Basel)
Volume : 12

Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel.

Auteurs : Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, Kerger J, Gil T, Piccart-Gebhart M, Awada A, Demetter P, Larsimont D, Hendlisz A, Aftimos P, Sclafani F
Année : 2020
Journal : Acta oncol (Stockholm)
Volume : 59
Pages : 1438-1446

Treatment compliance in early-stage anal cancer.

Auteurs : Pretta A, Trevisi E, Bregni G, Deleporte A, Hendlisz A, Sclafani F
Année : 2020
Journal : Ann Oncol
Volume : 31
Pages : 1282-1284

Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice.

Auteurs : Bregni G, Akin Telli T, Camera S, Deleporte A, Moretti L, Bali MA, Liberale G, Holbrechts S, Hendlisz A, Sclafani F
Année : 2020
Journal : Cancer Treat Rev
Volume : 83
Pages : 101948

Grey areas and evidence gaps in the management of rectal cancer as revealed by comparing recommendations from clinical guidelines.

Auteurs : Bregni G, Akin Telli T, Camera S, Baratelli C, Shaza L, Deleporte A, Moretti L, Bali MA, Liberale G, Hendlisz A, Sclafani F
Année : 2020
Journal : Cancer Treat Rev
Volume : 82
Pages : 101930

PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.

Auteurs : Akin Telli T, Bregni G, Camera S, Deleporte A, Hendlisz A, Sclafani F
Année : 2020
Journal : Cancer Lett
Volume : 469
Pages : 142-150

MOMENTUM: A Phase I Trial Investigating 2 Schedules of Capecitabine With Aflibercept in Patients With Gastrointestinal and Breast Cancer.

Auteurs : Camera S, Deleporte A, Bregni G, Trevisi E, Pretta A, Telli TA, Polastro L, Gombos A, Kayumba A, Ameye L, Piccart-Gebhart M, Awada A, Sclafani F, Hendlisz A
Année : 2020
Journal : Clin Colorectal Cancer
Volume : 19
Pages : 311-318.e1

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Auteurs : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Année : 2018
Journal : Eur J Cancer
Volume : 89
Pages : 42-48